A phase 1/2, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of D-1553 in subjects with advanced or metastatic solid tumors with KRasG12C mutation
- Richardson, Gary (Primary Chief Investigator (PCI))
- Lai, Li Hoon (Project Manager)
Project: Research